{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T14:46:49Z","timestamp":1785941209583,"version":"3.56.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T00:00:00Z","timestamp":1785888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T00:00:00Z","timestamp":1785888000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Egypt Natl Canc Inst"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This study aimed to systematically synthesize and separately quantify the pooled safety profiles of bispecific antibodies (BsAbs) targeting PD-1\/CTLA-4 or PD-1\/VEGF in patients with non-small cell lung cancer (NSCLC), and to descriptively summarize class-specific safety patterns.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Following PRISMA guidelines, we systematically reviewed prospective clinical trials published through January 2026. A total of 17 studies, encompassing 1802 patients, were included. Single-arm proportion meta-analyses were conducted separately for each BsAb class using random-effects models. No formal between-class statistical comparison was performed. Given the clinical heterogeneity across included cohorts, including differences in study phase, treatment line, molecular subtype, and treatment regimen, pooled estimates were interpreted descriptively. Subgroup analyses by treatment regimen, treatment line, and individual BsAb agent were considered exploratory. Because of the limited number of cohorts within each phase stratum, the impact of study phase was assessed descriptively rather than through formal stratified meta-analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In separate pooled analyses, the incidence of grade 3 or higher treatment-related adverse events (TRAEs) was 41.79% for PD-1\/CTLA-4 BsAbs and 43.51% for PD-1\/VEGF BsAbs. Exploratory subgroup analyses suggested different patterns of heterogeneity across the available cohorts. In PD-1\/CTLA-4 BsAb studies, AE rates appeared to vary across individual agents, whereas in PD-1\/VEGF BsAb studies, higher AE rates were observed mainly in chemotherapy-containing regimens. These observations should be interpreted cautiously because they may reflect differences in the distribution of included agents, patient populations, study phases, and treatment strategies rather than inherent class-specific toxicity mechanisms. Regarding tolerability, the pooled treatment discontinuation rate due to TRAEs was 10.26% in the PD-1\/CTLA-4 analysis and 4.44% in the PD-1\/VEGF analysis. The pooled incidence of immune-related adverse events (irAEs) was 46.68% in the PD-1\/CTLA-4 analysis and 27.10% in the PD-1\/VEGF analysis, whereas the pooled rates of grade 3 or higher irAEs were low in both analyses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This systematic review provides a descriptive synthesis of available safety data for PD-1\/CTLA-4 and PD-1\/VEGF BsAbs in NSCLC. Because the included cohorts differed substantially in study phase, treatment line, molecular background, and concomitant therapies, the pooled AE estimates should not be interpreted as direct comparative evidence. Instead, the findings should be viewed as hypothesis-generating signals that require validation in more homogeneous prospective studies or head-to-head trials.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s43046-026-00387-2","type":"journal-article","created":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T13:49:42Z","timestamp":1785937782000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pooled safety profiles of bispecific antibodies targeting PD-1\/CTLA-4 or PD-1\/VEGF in non-small cell lung cancer: a systematic review and single-arm meta-analysis"],"prefix":"10.1186","volume":"38","author":[{"given":"Jiayun","family":"Ma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-1291-4788","authenticated-orcid":false,"given":"Weixing","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,5]]},"reference":[{"issue":"4","key":"387_CR1","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1016\/S2213-2600(24)00428-4","volume":"13","author":"G Luo","year":"2025","unstructured":"Luo G, Zhang Y, Rumgay H, Morgan E, Langselius O, Vignat J, Colombet M, Bray F. Estimated worldwide variation and trends in incidence of lung cancer by histological subtype in 2022 and over time: a population-based study. Lancet Respir Med. 2025;13(4):348\u201363.","journal-title":"Lancet Respir Med"},{"issue":"3","key":"387_CR2","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"Cancer J Clin"},{"issue":"6","key":"387_CR3","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/j.it.2019.04.002","volume":"40","author":"KE Pauken","year":"2019","unstructured":"Pauken KE, Dougan M, Rose NR, Lichtman AH, Sharpe AH. Adverse Events Following Cancer Immunotherapy: Obstacles and Opportunities. Trends Immunol. 2019;40(6):511\u201323.","journal-title":"Trends Immunol"},{"key":"387_CR4","doi-asserted-by":"publisher","unstructured":"Ephraim R, Fraser S, Nurgali K, Apostolopoulos V. Checkpoint markers and tumor microenvironment: What do we know? Cancers (Basel). 2022;14(15):3788. https:\/\/doi.org\/10.3390\/cancers14153788.","DOI":"10.3390\/cancers14153788"},{"issue":"11","key":"387_CR5","doi-asserted-by":"publisher","first-page":"1992","DOI":"10.1200\/JCO.22.01989","volume":"41","author":"MC Garassino","year":"2023","unstructured":"Garassino MC, Gadgeel S, Speranza G, Felip E, Esteban E, D\u00f3mine M, Hochmair MJ, Powell SF, Bischoff HG, Peled N, et al. Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non-Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study. J Clin Oncol. 2023;41(11):1992\u20138.","journal-title":"J Clin Oncol"},{"issue":"11","key":"387_CR6","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1200\/JCO.22.01990","volume":"41","author":"S Novello","year":"2023","unstructured":"Novello S, Kowalski DM, Luft A, G\u00fcm\u00fc\u015f M, Vicente D, Mazi\u00e8res J, Rodr\u00edguez-Cid J, Tafreshi A, Cheng Y, Lee KH, et al. Pembrolizumab Plus Chemotherapy in Squamous Non-Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study. J Clin Oncol. 2023;41(11):1999\u20132006.","journal-title":"J Clin Oncol"},{"issue":"4","key":"387_CR7","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.ccell.2020.03.017","volume":"37","author":"AJ Schoenfeld","year":"2020","unstructured":"Schoenfeld AJ, Hellmann MD. Acquired Resistance to Immune Checkpoint Inhibitors. Cancer Cell. 2020;37(4):443\u201355.","journal-title":"Cancer Cell"},{"issue":"21","key":"387_CR8","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1056\/NEJMoa1910231","volume":"381","author":"MD Hellmann","year":"2019","unstructured":"Hellmann MD, Paz-Ares L, Bernabe Caro R, Zurawski B, Kim SW, Carcereny Costa E, Park K, Alexandru A, Lupinacci L, de la Mora Jimenez E, et al. Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer. N Engl J Med. 2019;381(21):2020\u201331.","journal-title":"N Engl J Med"},{"issue":"5","key":"387_CR9","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/nrclinonc.2018.29","volume":"15","author":"D Fukumura","year":"2018","unstructured":"Fukumura D, Kloepper J, Amoozgar Z, Duda DG, Jain RK. Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges. Nat Rev Clin Oncol. 2018;15(5):325\u201340.","journal-title":"Nat Rev Clin Oncol"},{"issue":"6","key":"387_CR10","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1080\/14740338.2021.1867100","volume":"20","author":"P Abdayem","year":"2021","unstructured":"Abdayem P, Planchard D. Safety of current immune checkpoint inhibitors in non-small cell lung cancer. Expert Opin Drug Saf. 2021;20(6):651\u201367.","journal-title":"Expert Opin Drug Saf"},{"issue":"2","key":"387_CR11","first-page":"513","volume":"37","author":"L Wang","year":"2021","unstructured":"Wang L, Wei Z, Xiong W, Bai S, Yu C, Yang Z. [Bispecific antibodies in clinical tumor therapy]. Sheng Wu Gong Cheng Xue Bao. 2021;37(2):513\u201329.","journal-title":"Sheng Wu Gong Cheng Xue Bao"},{"key":"387_CR12","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1111\/j.1600-065X.1995.tb00082.x","volume":"145","author":"C Renner","year":"1995","unstructured":"Renner C, Pfreundschuh M. Tumor therapy by immune recruitment with bispecific antibodies. Immunol Rev. 1995;145:179\u2013209.","journal-title":"Immunol Rev"},{"issue":"10481","key":"387_CR13","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/S0140-6736(24)02722-3","volume":"405","author":"A Xiong","year":"2025","unstructured":"Xiong A, Wang L, Chen J, Wu L, Liu B, Yao J, Zhong H, Li J, Cheng Y, Sun Y, et al. Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China. Lancet. 2025;405(10481):839\u201349.","journal-title":"Lancet"},{"key":"387_CR14","doi-asserted-by":"publisher","first-page":"112936","DOI":"10.1016\/j.ejca.2023.05.024","volume":"190","author":"A Xiong","year":"2023","unstructured":"Xiong A, Li W, Li X, Fan Y, Ma Z, Fang J, Xie Q, Zhuang W, Kang M, Wang J, et al. Efficacy and safety of KN046, a novel bispecific antibody against PD-L1 and CTLA-4, in patients with non-small cell lung cancer who failed platinum-based chemotherapy: a phase II study. Eur J Cancer. 2023;190:112936.","journal-title":"Eur J Cancer"},{"key":"387_CR15","doi-asserted-by":"publisher","first-page":"1605877","DOI":"10.3389\/fimmu.2025.1605877","volume":"16","author":"Y Zhang","year":"2025","unstructured":"Zhang Y, Wang H, Yang X, Lei C. Dual-target immunotherapies in NSCLC: a systematic review and meta-analysis of randomized clinical trials. Front Immunol. 2025;16:1605877.","journal-title":"Front Immunol"},{"key":"387_CR16","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.","journal-title":"BMJ"},{"issue":"10","key":"387_CR17","first-page":"Ed000142","volume":"10","author":"M Cumpston","year":"2019","unstructured":"Cumpston M, Li T, Page MJ, Chandler J, Welch VA, Higgins JP, Thomas J. Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions. Cochrane Database Syst Rev. 2019;10(10):Ed000142.","journal-title":"Cochrane Database Syst Rev"},{"issue":"9","key":"387_CR18","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","volume":"25","author":"A Stang","year":"2010","unstructured":"Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25(9):603\u20135.","journal-title":"Eur J Epidemiol"},{"key":"387_CR19","doi-asserted-by":"crossref","unstructured":"Zhang L, Fang W, Zhao Y, Luo Y, Yang R, Huang Y, He Z, Zhao H, Li M, Li K. 1348 Final overall survival analysis of HARMONi-A study comparing ivonescimab plus chemotherapy to chemotherapy alone in patients with EGFR+ NSCLC progressed on EGFR-TKI treatment. In.: BMJ Publishing Group Ltd; 2025.","DOI":"10.1136\/jitc-2025-SITC2025.1348"},{"issue":"10","key":"387_CR20","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1016\/j.jtho.2025.09.017","volume":"20","author":"J Goldman","year":"2025","unstructured":"Goldman J, Passaro A, Laskin J, Rodrigues-Abreu D, Calles A, Bazhenova L, Russo GL, Leighl N, Cappuzzo F, Girard N. PL02. 12 Ivonescimab vs placebo plus chemo, phase 3 in patients with EGFR+ NSCLC progressed with 3rd gen EGFR-TKI treatment: HARMONi. J Thorac Oncol. 2025;20(10):S2\u20133.","journal-title":"J Thorac Oncol"},{"issue":"10515","key":"387_CR21","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1016\/S0140-6736(25)01848-3","volume":"406","author":"Z Chen","year":"2025","unstructured":"Chen Z, Yang F, Jiang Z, Sun L, Wu L, Han Z, Fan Y, Zhao Y, Li X, Xu H, et al. Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (HARMONi-6): a randomised, double-blind, phase 3 trial. Lancet. 2025;406(10515):2078\u201388.","journal-title":"Lancet"},{"issue":"10","key":"387_CR22","doi-asserted-by":"publisher","first-page":"S96","DOI":"10.1016\/j.jtho.2025.09.175","volume":"20","author":"Y Zheng","year":"2025","unstructured":"Zheng Y, Xu N, Yang F, Song X, Wang W, Zhang G, Yang L, Zhang Z, Wang M, Qian S. MA10. 03 Efficacy and Safety of Cadonilimab Plus Pulocimab in NSCLC Patients Who Progressed Following Prior Immunotherapy: A Phase 1b\/2 Study. J Thorac Oncol. 2025;20(10):S96.","journal-title":"J Thorac Oncol"},{"issue":"1","key":"387_CR23","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s13045-025-01728-9","volume":"18","author":"Y Zhang","year":"2025","unstructured":"Zhang Y, Huang Y, Yang Y, Zhao Y, Zhao H, Zhou N, Chen L, Zhou T, Chen G, Zhao S, et al. Iparomlimab and tuvonralimab (QL1706) plus chemotherapy and bevacizumab for EGFR-mutant patients with advanced non-small cell lung cancer after failure of EGFR-tyrosine kinase inhibitors: updated results from cohort 5 in the DUBHE-L-201 study. J Hematol Oncol. 2025;18(1):75.","journal-title":"J Hematol Oncol"},{"key":"387_CR24","doi-asserted-by":"publisher","unstructured":"Zhang L, Zhao Y, Meng X, Huang Y, Fang W, Yang Y, et al. 133P The efficacy and safety of KN046 combined with axitinib for previously untreated and checkpoint inhibitor-treated advanced non-small cell lung cancer: A single-arm, open-label, multicenter phase II clinical trial. Immuno-Oncol Technol. 2024;24:100762. https:\/\/doi.org\/10.1016\/j.iotech.2024.100762.","DOI":"10.1016\/j.iotech.2024.100762"},{"issue":"10","key":"387_CR25","doi-asserted-by":"publisher","first-page":"S614","DOI":"10.1016\/j.jtho.2024.09.1152","volume":"19","author":"L Wang","year":"2024","unstructured":"Wang L, Su C. EP. 11D. 01 a phase II study of cadonilimab plus chemotherapy as first-line treatment for PD-L1-negative advanced non-small cell lung cancer: LungCadX. J Thorac Oncol. 2024;19(10):S614.","journal-title":"J Thorac Oncol"},{"issue":"10","key":"387_CR26","doi-asserted-by":"publisher","first-page":"S33","DOI":"10.1016\/j.jtho.2024.09.062","volume":"19","author":"D Spigel","year":"2024","unstructured":"Spigel D, Ahn M-J, Majem M, Rodr\u00edguez LM, Lee K, Carcereny E, Hern\u00e1ndez A, Insa A, Cho E, Besse B. OA11. 04 volrustomig+ platinum doublet chemotherapy (CTx) in first-line non-small cell lung cancer (NSCLC): Phase 1b trial update. J Thorac Oncol. 2024;19(10):S33\u20134.","journal-title":"J Thorac Oncol"},{"issue":"1","key":"387_CR27","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/s41392-023-01731-x","volume":"9","author":"Y Huang","year":"2024","unstructured":"Huang Y, Yang Y, Zhao Y, Zhao H, Zhou N, Zhang Y, Chen L, Zhou T, Chen G, Wu T, et al. QL1706 (anti-PD-1 IgG4\/CTLA-4 antibody) plus chemotherapy with or without bevacizumab in advanced non-small cell lung cancer: a multi-cohort, phase II study. Signal Transduct Target Ther. 2024;9(1):23.","journal-title":"Signal Transduct Target Ther"},{"issue":"3","key":"387_CR28","doi-asserted-by":"publisher","first-page":"101470","DOI":"10.1016\/j.xcrm.2024.101470","volume":"5","author":"Y Zhao","year":"2024","unstructured":"Zhao Y, Chen G, Li X, Wu J, Chang B, Hu S, Yang S, Xu T, Liu Y, Wang N, et al. KN046, a bispecific antibody against PD-L1 and CTLA-4, plus chemotherapy as first-line treatment for metastatic NSCLC: A multicenter phase 2 trial. Cell Rep Med. 2024;5(3):101470.","journal-title":"Cell Rep Med"},{"issue":"3","key":"387_CR29","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1038\/s41416-023-02519-0","volume":"130","author":"B Chen","year":"2024","unstructured":"Chen B, Yao W, Li X, Lin G, Chu Q, Liu H, Du Y, Lin J, Duan H, Wang H, et al. A phase Ib\/II study of cadonilimab (PD-1\/CTLA-4 bispecific antibody) plus anlotinib as first-line treatment in patients with advanced non-small cell lung cancer. Br J Cancer. 2024;130(3):450\u20136.","journal-title":"Br J Cancer"},{"key":"387_CR30","doi-asserted-by":"publisher","first-page":"107355","DOI":"10.1016\/j.lungcan.2023.107355","volume":"184","author":"Y Zhao","year":"2023","unstructured":"Zhao Y, Ma Y, Fan Y, Zhou J, Yang N, Yu Q, Zhuang W, Song W, Wang ZM, Li B, et al. A multicenter, open-label phase Ib\/II study of cadonilimab (anti PD-1 and CTLA-4 bispecific antibody) monotherapy in previously treated advanced non-small-cell lung cancer (AK104-202 study). Lung Cancer. 2023;184:107355.","journal-title":"Lung Cancer"},{"issue":"3","key":"387_CR31","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/j.jtho.2023.10.014","volume":"19","author":"L Wang","year":"2024","unstructured":"Wang L, Luo Y, Ren S, Zhang Z, Xiong A, Su C, Zhou J, Yu X, Hu Y, Zhang X, et al. A Phase 1b Study of Ivonescimab, a Programmed Cell Death Protein-1 and Vascular Endothelial Growth Factor Bispecific Antibody, as First- or Second-Line Therapy for Advanced or Metastatic Immunotherapy-Naive NSCLC. J Thorac Oncol. 2024;19(3):465\u201375.","journal-title":"J Thorac Oncol"},{"key":"387_CR32","doi-asserted-by":"publisher","first-page":"S804","DOI":"10.1016\/j.annonc.2024.08.1312","volume":"35","author":"Y Wu","year":"2024","unstructured":"Wu Y, Wang Z, Cheng Y, Fang J, Meng X, Pan Y, Zhao H, Zhao Y, Su H, Sun M. 1255MO A phase II safety and efficacy study of PM8002\/BNT327 in combination with chemotherapy in patients with EGFR-mutated non-small cell lung cancer (NSCLC). Ann Oncol. 2024;35:S804.","journal-title":"Ann Oncol"},{"key":"387_CR33","doi-asserted-by":"publisher","first-page":"102106","DOI":"10.1016\/j.eclinm.2023.102106","volume":"62","author":"Y Zhao","year":"2023","unstructured":"Zhao Y, Chen G, Chen J, Zhuang L, Du Y, Yu Q, Zhuang W, Zhao Y, Zhou M, Zhang W, et al. AK112, a novel PD-1\/VEGF bispecific antibody, in combination with chemotherapy in patients with advanced non-small cell lung cancer (NSCLC): an open-label, multicenter, phase II trial. EClinicalMedicine. 2023;62:102106.","journal-title":"EClinicalMedicine"},{"issue":"9","key":"387_CR34","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/s41571-019-0218-0","volume":"16","author":"F Martins","year":"2019","unstructured":"Martins F, Sofiya L, Sykiotis GP, Lamine F, Maillard M, Fraga M, Shabafrouz K, Ribi C, Cairoli A, Guex-Crosier Y, et al. Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nat Rev Clin Oncol. 2019;16(9):563\u201380.","journal-title":"Nat Rev Clin Oncol"},{"issue":"2","key":"387_CR35","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1056\/NEJMra1703481","volume":"378","author":"MA Postow","year":"2018","unstructured":"Postow MA, Sidlow R, Hellmann MD. Immune-Related Adverse Events Associated with Immune Checkpoint Blockade. N Engl J Med. 2018;378(2):158\u201368.","journal-title":"N Engl J Med"},{"issue":"8","key":"387_CR36","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/s41573-019-0028-1","volume":"18","author":"AF Labrijn","year":"2019","unstructured":"Labrijn AF, Janmaat ML, Reichert JM, Parren P. Bispecific antibodies: a mechanistic review of the pipeline. Nat Rev Drug Discov. 2019;18(8):585\u2013608.","journal-title":"Nat Rev Drug Discov"},{"issue":"10","key":"387_CR37","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1016\/S1470-2045(23)00411-4","volume":"24","author":"X Gao","year":"2023","unstructured":"Gao X, Xu N, Li Z, Shen L, Ji K, Zheng Z, Liu D, Lou H, Bai L, Liu T, et al. Safety and antitumour activity of cadonilimab, an anti-PD-1\/CTLA-4 bispecific antibody, for patients with advanced solid tumours (COMPASSION-03): a multicentre, open-label, phase 1b\/2 trial. Lancet Oncol. 2023;24(10):1134\u201346.","journal-title":"Lancet Oncol"},{"issue":"12","key":"387_CR38","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1007\/s40265-022-01761-9","volume":"82","author":"SJ Keam","year":"2022","unstructured":"Keam SJ. Cadonilimab: First Approval. Drugs. 2022;82(12):1333\u20139.","journal-title":"Drugs"},{"issue":"12Supplement","key":"387_CR39","doi-asserted-by":"publisher","first-page":"CT016","DOI":"10.1158\/1538-7445.AM2022-CT016","volume":"82","author":"B Tran","year":"2022","unstructured":"Tran B, Voskoboynik M, Kim S-W, Lemech C, Carcereny E, Rha SY, Ahn M-J, Felip E, Lee KH, Alvarez EC. Abstract CT016: MEDI5752, a novel PD-1\/CTLA-4 bispecific checkpoint inhibitor for advanced solid tumors: First-in-human study. Cancer Res. 2022;82(12Supplement):CT016\u2013016.","journal-title":"Cancer Res"},{"issue":"5","key":"387_CR40","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/s41422-018-0031-9","volume":"28","author":"J Pol","year":"2018","unstructured":"Pol J, Kroemer G. Anti-CTLA-4 immunotherapy: uncoupling toxicity and efficacy. Cell Res. 2018;28(5):501.","journal-title":"Cell Res"},{"issue":"1","key":"387_CR41","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1172\/JCI123391","volume":"129","author":"C-CS Pai","year":"2019","unstructured":"Pai C-CS, Simons DM, Lu X, Evans M, Wei J, Wang Y-h, Chen M, Huang J, Park C, Chang A. Tumor-conditional anti-CTLA4 uncouples antitumor efficacy from immunotherapy-related toxicity. J Clin Investig. 2019;129(1):349\u201363.","journal-title":"J Clin Investig"},{"issue":"1","key":"387_CR42","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s12943-019-0974-6","volume":"18","author":"M Yi","year":"2019","unstructured":"Yi M, Jiao D, Qin S, Chu Q, Wu K, Li A. Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment. Mol Cancer. 2019;18(1):60.","journal-title":"Mol Cancer"},{"issue":"1","key":"387_CR43","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1093\/annonc\/mds590","volume":"24","author":"JC Soria","year":"2013","unstructured":"Soria JC, Mauguen A, Reck M, Sandler AB, Saijo N, Johnson DH, Burcoveanu D, Fukuoka M, Besse B, Pignon JP. Systematic review and meta-analysis of randomised, phase II\/III trials adding bevacizumab to platinum-based chemotherapy as first-line treatment in patients with advanced non-small-cell lung cancer. Ann Oncol. 2013;24(1):20\u201330.","journal-title":"Ann Oncol"},{"issue":"4","key":"387_CR44","first-page":"348","volume":"22","author":"J Wen","year":"2025","unstructured":"Wen J, Cui W, Yin X, Chen Y, Liu A, Wang Q, Meng X. Application and future prospects of bispecific antibodies in the treatment of non-small cell lung cancer. Cancer Biol Med. 2025;22(4):348\u201375.","journal-title":"Cancer Biol Med"},{"issue":"8","key":"387_CR45","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1038\/nrclinonc.2016.58","volume":"13","author":"C Boutros","year":"2016","unstructured":"Boutros C, Tarhini A, Routier E, Lambotte O, Ladurie FL, Carbonnel F, Izzeddine H, Marabelle A, Champiat S, Berdelou A, et al. Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination. Nat Rev Clin Oncol. 2016;13(8):473\u201386.","journal-title":"Nat Rev Clin Oncol"},{"issue":"8","key":"387_CR46","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/nrclinonc.2009.94","volume":"6","author":"HX Chen","year":"2009","unstructured":"Chen HX, Cleck JN. Adverse effects of anticancer agents that target the VEGF pathway. Nat reviews Clin Oncol. 2009;6(8):465\u201377.","journal-title":"Nat reviews Clin Oncol"},{"issue":"2","key":"387_CR47","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1161\/HYPERTENSIONAHA.117.08856","volume":"70","author":"RM Touyz","year":"2017","unstructured":"Touyz RM, Lang NN, Herrmann J, van den Meiracker AH, Danser AHJ. Recent Advances in Hypertension and Cardiovascular Toxicities With Vascular Endothelial Growth Factor Inhibition. Hypertens (Dallas Tex: 1979). 2017;70(2):220\u20136.","journal-title":"Hypertens (Dallas Tex: 1979)"},{"issue":"2","key":"387_CR48","doi-asserted-by":"publisher","first-page":"otag050","DOI":"10.1093\/crocol\/otag050","volume":"360","author":"C Ma","year":"2026","unstructured":"Ma C, Collins EB, Wang ST, Teng Y, Stevens W, Panaccione R, Sharma D, Joshi N, Morisset PA, Atreya R, et al. Considerations in reviewing network meta-analyses of heterogeneous clinical trial designs: a methodological review in Crohn\u2019s disease and ulcerative colitis. Crohn\u2019s colitis. 2026;360(2):otag050.","journal-title":"Crohn\u2019s colitis"},{"key":"387_CR49","doi-asserted-by":"publisher","first-page":"e2400907","DOI":"10.1200\/PO-24-00907","volume":"9","author":"L Huang","year":"2025","unstructured":"Huang L, Zhang S, Sun L, Ma J, Han C. Immune Checkpoint Inhibitors in Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor-Resistant Chemotherapy-Na\u00efve Advanced Non-Small Cell Lung Cancer: A Meta-Analysis Based on Eight Randomized Trials. JCO Precis Oncol. 2025;9:e2400907.","journal-title":"JCO Precis Oncol"},{"issue":"5","key":"387_CR50","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1111\/j.1365-2753.2008.00986.x","volume":"14","author":"JP Ioannidis","year":"2008","unstructured":"Ioannidis JP. Interpretation of tests of heterogeneity and bias in meta-analysis. J Eval Clin Pract. 2008;14(5):951\u20137.","journal-title":"J Eval Clin Pract"},{"issue":"1","key":"387_CR51","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1186\/s13643-025-02831-1","volume":"14","author":"S Iaquinto","year":"2025","unstructured":"Iaquinto S, B\u00fchrer L, Feldmann M, Latal B, Held U. How to quantify between-study heterogeneity in single-arm evidence synthesis?-It depends! Syst Rev. 2025;14(1):138.","journal-title":"Syst Rev"},{"key":"387_CR52","doi-asserted-by":"publisher","unstructured":"Yaskolko M, Liu C, Barsouk A, Sussman JH, Barsouk AA. Disparities in Non-Small Cell Lung Cancer (NSCLC) by Age, Sex, and Race: A Systematic Review and Meta-Analysis of Immune Checkpoint Inhibitor (ICI) Trials. Cancers (Basel). 2026;18(1):128. https:\/\/doi.org\/10.3390\/cancers18010128.","DOI":"10.3390\/cancers18010128"},{"issue":"6","key":"387_CR53","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1093\/annonc\/mdx108","volume":"28","author":"N Chaput","year":"2017","unstructured":"Chaput N, Lepage P, Coutzac C, Soularue E, Le Roux K, Monot C, Boselli L, Routier E, Cassard L, Collins M, et al. Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab. Ann Oncol. 2017;28(6):1368\u201379.","journal-title":"Ann Oncol"},{"key":"387_CR54","doi-asserted-by":"publisher","unstructured":"Ko\u015bmider K, Kozakiewicz A, Krawczyk P, Kieszko R, Szklener K, Sk\u00f3rzewska M, Wojas-Krawczyk K, Kalinka E, Milanowski J. Immune-Related Adverse Events of Checkpoint Inhibitors and Human Leukocyte Antigen System: A Review. ImmunoTargets Therapy. 2025:1455\u201378. https:\/\/doi.org\/10.2147\/ITT.S548443.","DOI":"10.2147\/ITT.S548443"}],"container-title":["Journal of the Egyptian National Cancer Institute"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43046-026-00387-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s43046-026-00387-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43046-026-00387-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T13:49:54Z","timestamp":1785937794000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s43046-026-00387-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,5]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["387"],"URL":"https:\/\/doi.org\/10.1186\/s43046-026-00387-2","relation":{},"ISSN":["2589-0409"],"issn-type":[{"value":"2589-0409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,5]]},"assertion":[{"value":"19 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"54"}}